about
Preclinical Assessment of Viral Vectored and Protein Vaccines Targeting the Duffy-Binding Protein Region II of Plasmodium VivaxStructure of malaria invasion protein RH5 with erythrocyte basigin and blocking antibodiesProduction of full-length soluble Plasmodium falciparum RH5 protein vaccine using a Drosophila melanogaster Schneider 2 stable cell line systemExternal quality assurance of malaria nucleic acid testing for clinical trials and eradication surveillanceImpact on malaria parasite multiplication rates in infected volunteers of the protein-in-adjuvant vaccine AMA1-C1/Alhydrogel+CPG 7909.The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody.Combining viral vectored and protein-in-adjuvant vaccines against the blood-stage malaria antigen AMA1: report on a phase 1a clinical trial.Optimising Controlled Human Malaria Infection Studies Using Cryopreserved P. falciparum Parasites Administered by Needle and Syringe.A PfRH5-based vaccine is efficacious against heterologous strain blood-stage Plasmodium falciparum infection in aotus monkeys.Increased sample volume and use of quantitative reverse-transcription PCR can improve prediction of liver-to-blood inoculum size in controlled human malaria infection studiesEvaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals.The requirement for potent adjuvants to enhance the immunogenicity and protective efficacy of protein vaccines can be overcome by prior immunization with a recombinant adenovirusTailoring subunit vaccine immunogenicity: maximizing antibody and T cell responses by using combinations of adenovirus, poxvirus and protein-adjuvant vaccines against Plasmodium falciparum MSP1.Enhancing blockade of Plasmodium falciparum erythrocyte invasion: assessing combinations of antibodies against PfRH5 and other merozoite antigens.ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans.The utility of Plasmodium berghei as a rodent model for anti-merozoite malaria vaccine assessment.Demonstration of the Blood-Stage Plasmodium falciparum Controlled Human Malaria Infection Model to Assess Efficacy of the P. falciparum Apical Membrane Antigen 1 Vaccine, FMP2.1/AS01Comparison of modeling methods to determine liver-to-blood inocula and parasite multiplication rates during controlled human malaria infectionGerminal Center B Cell and T Follicular Helper Cell Responses to Viral Vector and Protein-in-Adjuvant Vaccines.Neutralization of Plasmodium falciparum merozoites by antibodies against PfRH5.Assessment of antibody-dependent respiratory burst activity from mouse neutrophils on Plasmodium yoelii malaria challenge outcome.Challenges of assessing the clinical efficacy of asexual blood-stage Plasmodium falciparum malaria vaccinesAccelerating the clinical development of protein-based vaccines for malaria by efficient purification using a four amino acid C-terminal 'C-tag'.Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions.Production, quality control, stability, and potency of cGMP-produced RH5.1 protein vaccine expressed in S2 cellsEvaluation of Point-of-care Activated Partial Thromboplastin Time Testing by Comparison to Laboratory-based Assay for Control of Intravenous HeparinThe Difficult Venous Ulcer: Case Series of 177 Ulcers Referred for Vascular Surgical Opinion Following Failure of Conservative ManagementA simian-adenovirus-vectored rabies vaccine suitable for thermostabilisation and clinical development for low-cost single-dose pre-exposure prophylaxisA defined mechanistic correlate of protection against Plasmodium falciparum malaria in non-human primatesSimian adenovirus vector production for early-phase clinical trials: A simple method applicable to multiple serotypes and using entirely disposable product-contact componentsFunctional Comparison of Blood-Stage Plasmodium falciparum Malaria Vaccine Candidate Antigens.Human Antibodies that Slow Erythrocyte Invasion Potentiate Malaria-Neutralizing Antibodies
P50
Q24273364-3B43EC17-FA52-4A26-91F0-C064B997A6DFQ24289322-4C568DE8-0D9D-4959-BA1C-A91D29F2E0FCQ26700012-555850CA-F09B-4A91-84D5-496AE2A13A67Q28538917-387C7A75-A56D-454D-8BBF-F9EC1F27623AQ33974904-6643C0AD-F2D9-491F-BEFA-2793E6810085Q34241973-7CD508F4-0382-495F-801D-95C645D9CFF7Q34600955-9CC54D6A-477B-424F-9195-C7BB1B2AE4E9Q34792326-08DD1C83-2F2D-404D-B797-40CAD1F4373AQ34978590-FF68AB08-3ED0-477E-8886-161104E520F8Q35052801-782A0A9B-6254-4C29-BF49-841440B8D6FDQ35163318-AED44A4F-185A-4862-B107-E96294EA99F3Q35177864-73C1DB07-4583-4EC1-BD07-EB153D6C5457Q36114395-BFBD6A2B-850F-4A22-BD3F-7D17FA610CDBQ36384456-FC4579FF-4FF9-4A15-9F2E-D69F9782CCAFQ36460499-E50F75FB-20E8-494B-A68B-91F33FAEAB2CQ36785777-EDB0046C-26F0-4F46-B0D8-8BBFD16B1516Q36871970-F1E82F72-86BC-4DCC-A218-CED56274230EQ36936348-1BBFDF8E-7D05-4F97-9A66-9F45035A7974Q37153663-6A4F0589-1311-4C55-A0D1-DEF12B67BDF2Q37412559-4B2376A4-7224-4C62-A094-A92D82CE8A2CQ37496763-59213B15-B73A-4808-89F5-48882F94C1A7Q37530299-5EE3D49D-7998-4FC1-9DCB-59AE8414B5BEQ38718229-5E7D6605-A66C-4EFB-808F-AF6DC48891EEQ47576664-6320BB54-9846-4BEF-9987-4CBDDE966728Q56342201-431BBF4F-3E9B-45F9-B761-E7925F5D6378Q57195181-27E24D90-6A08-482F-B90E-ACBA7BDEF125Q57195183-9B37620F-B168-4F8C-BD93-74E6FC78E229Q58106628-A219B928-3941-4DA9-A1F3-1805A0F0CC2FQ63634462-35236EE2-4F3B-48B3-AFB9-C22C4DF6729CQ64374679-01954E04-5F21-4012-BC70-B5252D659759Q64967277-7611763D-8BAD-4460-940A-AEEAAC036AC4Q92781089-8C124C37-146B-4C1D-9B9F-F44219EE9105
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Alexander D Douglas
@ast
Alexander D Douglas
@en
Alexander D Douglas
@es
Alexander D Douglas
@nl
Alexander D Douglas
@sl
type
label
Alexander D Douglas
@ast
Alexander D Douglas
@en
Alexander D Douglas
@es
Alexander D Douglas
@nl
Alexander D Douglas
@sl
prefLabel
Alexander D Douglas
@ast
Alexander D Douglas
@en
Alexander D Douglas
@es
Alexander D Douglas
@nl
Alexander D Douglas
@sl
P1053
E-7040-2012
P106
P21
P31
P3829
P496
0000-0002-5410-7562